局限期小细胞肺癌每日两次胸部放疗两种方案随机2期试验中放疗治疗计划的评估
该研究回顾了随机2期试验中166例接受至少1次胸部放疗的局限期小细胞肺癌患者的治疗计划,比较60 Gy/40次与45 Gy/30次每日两次方案的剂量体积数据、方案依从性及与放射性毒性的关联。结果显示危及器官剂量多在方案限值内,两组计划参数均衡,支持高剂量组生存获益源于更高剂量。
要点
- 60 Gy/40次组食管平均剂量25.5 Gy与21%≥3级急性食管炎相关,45 Gy/30次组为24.3 Gy与18%相关。
- 60 Gy/40次组肺平均剂量16.5 Gy、V20 Gy 29.5%、V5 Gy 65.6%时≥3级肺炎发生率为4%,45 Gy/30次组无≥3级肺炎。
- 两组计划技术、危及器官再勾画体积变化百分比、计划靶体积、相对剂量和侧别均衡,支持生存获益源于更高剂量。
核心结论
- 严重放射性毒性发生率在其他近期试验范围内,报告的危及器官剂量 appears to be safe。
- 治疗计划参数在随机分组间均衡,支持每日两次60 Gy/40次方案的生存获益源于更高剂量。
研究设计与样本
- 随机2期试验中170例计划接受4周期铂类/依托泊苷化疗并随机接受每日两次胸部放疗60 Gy/40次或45 Gy/30次,分析其中至少接受1次放疗的166例患者的治疗计划。
主要发现
- 最常见的治疗计划技术为三维适形放疗(67%)。
- 两组危及器官报告的剂量体积参数第75百分位数均在方案推荐限值内。
- 食管平均剂量60 Gy/40次组为25.5 Gy(IQR 20.2-31.3)与21%≥3级急性食管炎相关,45 Gy/30次组为24.3 Gy(IQR 20.3-27.5)与18%相关。
- 60 Gy/40次组肺平均剂量16.5 Gy(IQR 15.8-16.9)、V20 Gy 29.5%(IQR 28.8-30.4)、V5 Gy 65.6%(IQR 61.5-68.7)时4%患者发生≥3级肺炎,45 Gy/30次组无≥3级肺炎。
- 治疗计划技术、原始与再勾画危及器官体积变化百分比、计划靶体积、相对剂量和侧别在随机分组间均衡。
关键数值与推荐
- 60 Gy/40次组食管平均剂量25.5 Gy(IQR 20.2-31.3),≥3级急性食管炎发生率21%。
- 45 Gy/30次组食管平均剂量24.3 Gy(IQR 20.3-27.5),≥3级急性食管炎发生率18%。
- 60 Gy/40次组肺平均剂量16.5 Gy(IQR 15.8-16.9)、V20 Gy 29.5%(IQR 28.8-30.4)、V5 Gy 65.6%(IQR 61.5-68.7),≥3级肺炎发生率4%。
- 45 Gy/30次组无≥3级肺炎。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There is limited clinical data for recommendations on how to deliver thoracic radiation therapy (TRT) concurrently with chemotherapy in limited-stage small cell lung cancer. We reviewed radiation therapy treatment plans in a randomized phase 2 trial comparing high-dose with standard-dose twice-daily TRT to assess treatment planning techniques, dose-volume data for target volumes and organs at risk (OARs), evaluate compliance with the protocol, associations with radiation-induced toxicity, and whether an imbalance in treatment planning parameters might be a reason for the large survival benefit of the higher dose (median overall survival 43.6 vs 22.6 months). METHODS AND MATERIALS: In the study, 170 patients were to receive 4 courses of platinum/etoposide and were randomized to receive twice-daily TRT of 60 Gy/40 fractions (fx) or 45 Gy/30 fx. TRT treatment plans for those who received 1 or more fx of TRT (n = 166) were analyzed. RESULTS: The most common treatment planning technique was 3-dimensional conformal radiation therapy (67%). The 75th percentile of the reported dose-volume parameters for the OARs were within the protocol-recommended limits for both groups. Mean doses to the esophagus of 25.5 Gy (IQR, 20.2-31.3; 60 Gy/40 fx) and 24.3 Gy (IQR, 20.3-27.5; 45 Gy/30 fx) were associated with 21% and 18% ≥ grade 3 acute esophagitis, respectively. In the 60 Gy/40 fx group, a mean dose to the lungs of 16.5 Gy (IQR, 15.8-16.9), V20 Gy of 29.5% (IQR, 28.8-30.4), and V5 Gy of 65.6% (IQR, 61.5-68.7) led to ≥ grade 3 pneumonitis in 4% of the patients. There was no ≥ grade 3 pneumonitis in the 45 Gy/30 fx group. The treatment planning techniques, the percentage change in volumes between original and redelineated OARs, planning target volumes, relative doses, and laterality were well balanced between the randomly assigned groups. CONCLUSIONS: Considering the incidences of severe radiation-induced toxicities were within the range of other recent trials, the reported doses to the OARs appear to be safe. Treatment planning parameters were well balanced between the randomly assigned groups, supporting that the survival benefit of the twice-daily 60 Gy/40 fx TRT schedule was due to the higher dose.
引用
- Levin N, Killingberg KT, Halvorsen TO, et al. Evaluation of Radiation Therapy Treatment Plans in a Randomized Phase 2 Trial Comparing 2 Schedules of Twice-Daily Thoracic Radiation Therapy in Limited Stage Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2024. PMID: 38583494. doi:10.1016/j.ijrobp.2024.03.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。